Heme oxygenase 1 (HO-1) plays an important role in vascular disease, transplantation, and inflammation. In animal models of acute and chronic inflammation, induction of HO-1 has antiinflammatory and cytoprotective properties. Since inflammation is an important trigger of osteoclastogenesis, we hypothesized that HO-1 might influence osteoclastogenesis. We investigated the effects of induction of HO-1 on osteoclast formation in vitro and in vivo. Furthermore, we addressed the role of HO-1 in inflammatory bone loss in humans. When HO-1 was induced by hemin in vitro, a significant dose-dependent inhibition of osteoclastogenesis was observed. Up-regulation of HO-1 was mediated by activation of MAPK and primarily prevented differentiation of osteoclast precursors to osteoclasts, whereas it did not affect mature osteoclasts. Anti-osteoclastogenic properties of hemin were based on a down-regulation of cfms, RANK, TRAF-6, and c-fos. In addition, induction of HO-1 inhibited TNF-triggered osteoclast differentiation in vitro as well as LPS-driven inflammatory bone loss in vivo. Furthermore, HO-1 induction suppressed osteoclastogenesis and bone destruction in a TNFmediated arthritis. In line, assessment of synovial tissue from rheumatoid arthritis patients revealed that osteoclasts are usually HO-1 negative. Moreover, serum levels of bilirubin, a metabolite of HO-1, were elevated in rheumatoid arthritis patients without bone damage, suggesting HO-1 affects bone loss in humans. In summary, these data indicate that HO-1 negatively regulates osteoclastogenesis, leading to a positive net balance of bone.
porphyrins like hemin, cobalt protoporphyrin (CoPP), and heme itself (1) . HO-1 is a stress response protein involved in vascular disease, transplantation, and inflammatory disorders (2, 3) . Loss of HO-1 leads to profound changes in cellular homeostasis in genetically deficient mice and humans (4) . HO-1 knockout mice and human HO-1 deficiency are associated with increased inflammation and oxidative stress, as manifested by diffuse inflammation in the liver and kidney, prominent endothelial damage with subsequent coagulation activation, hemolytic anemia, low bilirubin levels, and elevated ferritin levels with iron accumulation in liver and kidney (5) .
Moreover, several lines of evidence suggest that induction of HO-1 by hemin is antiinflammatory and anti-oxidative in vitro and in vivo. Additionally, HO-1 induction acts antiapoptotic in tumor cell lines such as gastric and thyroid cancer cells, suggesting that HO-1 protects cell and tissue integrity (6, 7) . With respect to the anti-inflammatory effect of HO-1 and its activator hemin, 1) endotoxin induced proinflammatory cytokine response is suppressed by pretreatment with hemin in macrophages in vitro (8) ; 2) hemin also suppresses zymosan induced TNF-α and IL-1 production in the air pouch model of inflammation (9) ; and 3) hemin mitigates inflammation in models of experimental glomerulonephritis and endotoxin-induced uveitis (10, 11) . In these models, up-regulation of HO-1 correlates with a reduction of serum levels of proinflammatory cytokines TNF, IL-1, and IL-6 as well as iNOS.
Among many other effects, inflammation is closely linked to bone loss. In fact, inflammatory disorders such as rheumatoid arthritis (RA) and Crohn's disease are precipitators of increased bone resorption and lead to osteoporosis and in the case of RA to local bone erosion (12, 13) . Typical inflammatory mediators like TNF-α and IL-1 are also strong inducers of osteoclastogenesis and therefore promote bone loss (14) . For instance, systemic overexpression of TNF (15) induces local and systemic inflammatory bone loss in mice (16) . On the other hand, mediators such as M-CSF and RANKL, which are essential for osteoclastogenesis, are expressed in inflammatory tissue (17, 18) .
In light of the anti-inflammatory effects of hemin, we hypothesized that HO-1 might be involved in bone regulation. We thus investigated the role of HO-1 on osteoclastogenesis in vitro and in vivo. Furthermore, we addressed whether HO-1 might play a role in bone resorption in human inflammatory disease.
MATERIALS AND METHODS

In vitro osteoclastogenesis and bone resorption assay
Murine osteoclasts were generated as described previously (19) . In brief, spleen cells from 6-wkold wild-type and human TNF-α transgenic (hTNFtg; tg197 strain, both C57BL6 genetic background) mice were cultured overnight in αMEM containing 10% fetal bovine serum (FBS) and 30 ng/ml M-CSF. After 24 h, nonadherent cells were harvested and subjected to gradient purification. Cells (1×10 6 cells/ml) were then seeded onto 48-well plates and supplemented with 30 ng/ml M-CSF and 50 ng/ml RANKL (both from R&D Diagnostics, Minneapolis, MN). Cultures were incubated in triplicates with complete medium change on day 3. Hemin, biliverdin, and bilirubin (all Frontier Scientific, Logan, UT) were added at different concentrations throughout the culture. In time-course experiments, hemin was added either throughout the culture (day 0 through day 5), from day 0 through day 3, or from day 3 through day 5 of culture. In another series of experiments, CD11b positive cells were selected by MACS (Miltenyi Biotec, Germany). CD11b+ cells (2×10 5 /well) were seeded onto 48-well plates and treated as described above. All animal procedures were approved by the local ethical committee.
Tartrate-resistant acid phosphatase (TRAP) staining for evaluation of osteoclast differentiation was performed after 5 days of culture using a leukocyte acid phosphatase kit (Sigma Chemicals, St. Louis, MO). Osteoclasts were identified by the presence of three or more nuclei and purple color. The resorption assay was performed on 0.4 mm thick bovine cortical bone slices as described previously (20) . Areas of bone resorption were planimetrically analyzed by Axioskop 2 microscope (Zeiss, Jena, Germany) and Osteomeasure Analysis System (Osteometrics, Decatur, GA).
Cell viability assays
Cell proliferation was measured using the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) colorimetric assay (Cell Proliferation Kit I, Roche Diagnostics, Mannheim, Germany). Briefly, osteoclasts were generated as described above. Cell proliferation was measured 6 h after restimulation on day 3 by incubating with MTT labeling reagent (10 µl/100 µl medium) for 4 h in a humidified atmosphere. Supernatant was transferred into a microtiter plate for measurement of optical density at 550 nm (Cell Proliferation Kit I, Roche Diagnostics). To determine the apoptotic index, osteoclasts were generated as described above. The TUNEL assay (Roche) was performed 12 h after restimulation of the cells on day 3. The total number of cells was determined by staining with Kernechtrot. The apoptotic index was calculated as the ratio of TUNEL-positive cells compared with all cells.
Immunofluorescence analysis of HO-1
Osteoclast cultures were fixed with 3.7% paraformaldehyde solution in PBS (pH 8.4) at room temperature for 15 min and permeabilized by 0.1% Triton X-100 in PBS (10 min at room temperature). Nonspecific binding sites were blocked by 5% BSA before being incubated with a rabbit anti-HO-1 primary polyclonal antibody (dilution 1:50, Stressgen; Victoria, BC) or rabbit immunoglobulin (negative control) at 37°C for 1 h. Cells were then incubated with PEconjugated anti-rabbit IgG (dilution 1:100; Accurate Chemicals, Westbury, NY) at 37°C for 1 h and examined by fluorescence microscope Axioskop 2 (Zeiss).
RT-PCR
Total RNA was isolated from cultivated osteoclast precursors after 16 h of culture (HO-1) or osteoclasts 6 h after restimulation using the RNeasy mini kit (Qiagen, Hilden, Germany). One microgram of total RNA was used for first strand cDNA synthesis (Amersham Biosciences), and 0.5 µl of cDNA was then used for PCR using the following primers:
HO-1, 5′-TCCCAGACACCGCTCCTCCAG-3′ and 5′-GGATTTGGGGCTGCTGGTTTC-3′; cathepsin K, 5′-GGAAGAAGACTCACCAGAAGC-3′ and 5′-GTCATATAGCCGCCTCCACAG-3′; MMP-9 5′-CCTGTGTGTTCCCGTTCATCT-3′ and 5′-CGCTGGAATGATCTAAGCCCA-3′; β-actin 5′-TGTGATGGTGGGAATGGGTCAG-3′ and 5′-TTTGATGTCACGCACGATTTCC-3′.
ELISA for cathepsin K
An enzyme immunoassay for cathepsin K from Biomedica (Vienna, Austria) was used. The ELISA used in this study is based on antibodies specific for amino acids 1-20 and amino acids 196-210 of the mature enzyme. Briefly, the assay procedure consisted of incubating 50 μl supernatant from osteoclast culture with 200 μl horseradish peroxidase-labeled detection antibody on capture antibody coated plates at room temperature overnight. After a washing step to remove unbound detection antibody, the reaction was visualized by tetramethyl benzidine and stopped by adding 0.9% H 2 SO 4 . Extinction was measured at 450 nm. The lower detection limit of the assay was 1.1 pmol/l (0 standard + 5× SD).
Western blot analysis of cultured osteoclast precursors
Cultured osteoclast precursors were starved in serum-free DMEM for 2 h on day 1 of culture and stimulated with various concentrations (0−10 µM) of hemin for 30 min. Supernatants were removed, cells were washed twice in PBS and subsequently lysed in buffer and centrifuged (10 mM Tris, pH 7.4; 150 mM NaCl, 1 mM EDTA, 0.2% sodium deoxcholate, 1% NP 40, 1 mM NaF, 2 mM Na 3 VO 4 , and protease inhibitors). Protein extracts were separated on 12% SDS-PAGE and stained with phospho-specific antibodies against p38 MAPK, JNK, and ERK (Cell Signaling, Beverly, MA). For control purposes antibodies against total p38 MAPK, JNK, and ERK (Cell Signaling) and actin (Sigma-Aldrich) were used. For analysis of the dose dependency of HO-1 induction in osteoclast precursors, spleen cells at day 1 were stimulated with M-CSF (30 ng/ml) and hemin at various concentrations for 16 h. Protein extracts were prepared as described above and a polyclonal antibody against HO-1 (Stressgen, Victoria, Canada), and actin was applied. Additionally, polyclonal antibodies against RANK (Chemicon, Hampshire, UK), TRAF-6 and c-fos (both from Santa Cruz, Santa Cruz, CA) were employed on osteoclasts at day 4 of culture.
Subperiostal injection of LPS
Twelve-week-old wild-type mice were subjected to a local calvarial injection of E. coli lipopolysaccharide (LPS; Sigma) at 25 mg/kg body weight (n=6) or saline (n=3), as described previously (21) . Mice were treated with a single intraperitoneal injection of hemin (20 mg/kg body weight) or saline 24 h before LPS treatment. After 5 days, calvarial tissues were obtained and fixed in 4% paraformaldehyde and decalcified with 14% EDTA (Sigma) at 4°C adjusted to pH 7.2 by adding ammonium hydroxide (Sigma) for 4 days, and serial paraffin sections (2 µM) were stained for TRAP. TRAP staining was performed as described previously (22) . Osteoclast numbers per millimeter of eroded bone surface were determined by histomorphometry using Osteomeasure Analysis System (Osteometrics).
Treatment with HO-1 inducers for local bone loss in TNF transgenic mice
Human TNF transgenic mice (hTNFtg, C57Bl6 genetic background, tg197 strain, n=12), aged 7 wk, which develop severe erosive arthritis due to enhanced osteoclastogenesis (15) were divided into three treatment groups. The first group (control) received three daily injections with phosphate buffered saline (100 µl) intraperitoneally; the second group received 20 mg/kg cobalt protoporphyrin (CoPP, Frontier Scientific, Logan, UT), an inducer of HO-1, once daily; and the third group received 20 mg/kg CoPP three times daily. Mice were randomized according to paw swelling, grip strength and body weight. Treatment started at an early stage of arthritis and lasted for 1 wk. After the mice were killed, hind paws were obtained and fixed in 4% paraformaldehyde and decalcified in 14% EDTA (pH 7.2) at 4°C for 4 days. Serial paraffin sections (2 µM) were stained for TRAP. Osteoclast numbers per paw section and the area of local bone erosions per paw section were determined by histomorphometry using Osteomeasure Analysis System.
Immunohistochemistry for HO-1 in human RA synovial tissue
Synovial tissue samples were obtained from synovectomy and joint replacement surgery from five patients with RA. Patients fulfilled the American College of Rheumatology criteria for the diagnosis of RA. Specimens were fixed in 4% buffered formalin for 4-12 h, decalcified in 10% EDTA, and embedded in paraffin. After deparaffination, endogenous peroxidase activity was quenched by incubating the sections in 3% hydrogen peroxide in methanol. Antigen retrieval was carried out by incubating sections with protease type XIV (0.05% in PBS) for 5 min at 37°C. Nonspecific protein binding sites were blocked with 10% normal goat serum at room temperature for 10 min in a humidified chamber before incubating with rabbit anti-HO-1 antibody (Stressgen) or rabbit immunoglobulin (negative control) at a dilution of 1:800 at 37°C for 1 h. Reaction was visualized by a biotinylated goat anti-rabbit IgG avidin-biotin complex (DAKO, Glostrup, Denmark) and Vector DAB substrate kit (Sigma). Counterstaining with hematoxylin was performed. Quantification of immunohistochemical sections was performed by counting both total cell numbers and the numbers of positively stained cells from at least three different sites of each section.
Bilirubin levels in RA patients
RA patients (n=148) from our outpatient clinic were screened for total bilirubin level. The diagnosis of RA was made according to the American College of Rheumatology criteria (23) . Patients with pathologically elevated liver transaminases (aspartate aminotransferase >35 U/l, alanine aminotransferase >35 U/l) or cholestatic parameters (gamma-glutamyltransferase >36 U/l, alkaline phosphatase >105 U/l) were excluded. X-rays of hand and feet were available in all patients. Patients were assigned to two different groups according to the presence of radiographic signs of bone erosions: nonerosive (n=47) and erosive (n=101) RA patients. Groups were matched for age and sex. Additional matching for similar disease duration was done in a group of 94 RA patients.
Statistical analysis
Data are shown as means ± SE. Group mean values of histological data were compared by ANOVA including Bonferroni correction. For comparison of histological and clinical assessments paired and unpaired t tests were used.
RESULTS
Hemin inhibits osteoclastogenesis and bone resorption in vitro
To determine the effect of hemin on osteoclastogenesis in vitro, spleen cells were cultured with M-CSF and RANKL. When increasing doses of hemin were added to the culture from the beginning of the experiment (d0), a dose-dependent reduction in the number of osteoclasts was observed. Inhibitory effects started at concentrations of 10 µM and complete inhibition of osteoclastogenesis was achieved with hemin concentrations >25 µM ( Fig. 1A and B) . Thus hemin leads to a dose-dependent inhibition of osteoclast formation with an IC 50 of ~25 µM.
Due to the fact that the decrease of multinuclear TRAP positive cells was also accompanied by a reduction of mononuclear TRAP positive osteoclast precursor cells (data not shown), we hypothesized that hemin exerts its inhibitory effects at early stages of osteoclast differentiation. To further clarify this issue, hemin was added after 3 days of culture. Indeed, only minor effects on osteoclasts generation could be found under such conditions. Moreover, withdrawal of hemin after 3 days of culture could not rescue impaired osteoclastogenesis (Fig. 1C) . Taken together these data clearly indicate that hemin interferes with early stages of osteoclast differentiation.
To verify that hemin directly acts on osteoclast precursors and not via other cells present in the spleen cell culture, positively selected spleen CD11b+ monocytes (>90% purity) were cultured with M-CSF and RANKL together with hemin. Indeed, the extent of osteoclast inhibition under this condition was comparable to the effects seen with whole spleen cell cultures, indicating that hemin directly acts on osteoclast precursors (Fig. 1D) .
To examine if inhibition of osteoclastogenesis by hemin also reduces bone resorption, spleen cells were cultured with M-CSF and RANKL with and without of addition of hemin on bovine cortical bone slices for 6 days. Quantitative analysis of the area of resorption pits revealed a dramatic reduction of bone resorptive capacity ( Fig. 1E and F) .
Effect of hemin on cell viability and apoptosis in pre-osteoclast cells
To further elucidate the pathomechanisms leading to hemin-induced blockade of osteoclast precursors, cell viability and proliferation were tested by an MTT assay. Spleen cells were prepared as described above and stimulated with M-CSF and RANKL with or without the addition of hemin. At concentrations inhibiting osteoclast precursors, hemin did not reduce the proliferation of the cells (Fig. 2A) . Furthermore enhancement of apoptosis due to hemin could be excluded by TUNEL staining. On the contrary, as shown in Fig. 2B , hemin inhibited apoptosis dose dependently up to 70% starting at concentrations of 50 µM and above. These data clearly exclude cytotoxicity as well as increased apoptosis as underlying causes for diminished osteoclastogenesis.
Hemin dose dependently induces HO-1 in osteoclast precursor cells
To evaluate whether the hemin-induced blockade of osteoclast differentiation is associated with increased HO-1 production, RT-PCR and Western blotting were performed in early osteoclast precursors after 1 day of culture. HO-1 mRNA was strongly up-regulated already at concentrations of 10 µM, with no further induction up to 100 µM (Fig. 2C) . Analysis of HO-1 protein expression revealed a dose-dependent induction starting from 1 μM peaking at 10 μM of hemin (Fig. 2D) . Dose-dependent up-regulation of HO-1 by hemin was also observed after 4 days of culture. Immunofluorescence labeling revealed that HO-1 was primarily localized in the cytoplasm of mononuclear cells, whereas multinucleated osteoclasts did not show any HO-1 staining (Fig. 2E ). This suggests that hemin induces HO-1 and that up-regulation of HO-1 inversely correlates with osteoclast differentiation.
Hemin requires MAPK for the induction of HO-1 in osteoclast precursors
Induction of HO-1 is known to be regulated by MAP kinases p38, JNK, and ERK (24) . We next investigated which pathways were involved in hemin induced HO-1 production and therefore cultured osteoclast precursors in the presence of various concentration of hemin (Fig. 2F) . Western blot analysis revealed that osteoclast precursors treated with medium alone showed only a weak phosphorylation of p38, JNK, and ERK. Addition of hemin dose dependently increased phosphorylation of all three MAPK. Activation of p38 peaked at a dose of 1 μM of hemin, whereas JNK and ERK activation peaked at hemin doses of 5 μM. This suggests that hemin requires MAPK activation for the induction of HO-1.
Biliverdin is only partially responsible for the osteoclast blocking effects of hemin
To investigate whether biliverdin, a metabolite of HO-1, is responsible for the effects of hemin, we stimulated spleen cells with M-CSF and RANKL and added biliverdin in increasing concentrations. Biliverdin also inhibited osteoclast generation dose dependently, although the effect was less pronounced. Even at the highest dosage (100 µm) only a 50% inhibition of osteoclastogenesis was seen (Fig. 3A) . Since, in contrast to treatment with hemin, no complete inhibition of osteoclasts could be achieved with biliverdin, biliverdin production by HO-1 is only partially responsible for the osteoclast blocking effects of hemin.
Osteoclast-specific genes are down-regulated by hemin
To analyze the functional changes of osteoclastogenesis induced by hemin treatment, total RNA from osteoclast cultures was collected and RT-PCR for TRAP, calcitonin receptor (CTR), MMP-9, and cathepsin K expression was performed. At levels sufficient to block bone resorption in vitro, hemin reduced the mRNA levels of TRAP and CTR (Fig. 3B) . With increasing dosage of hemin, mRNA for these two molecules further decreased dose dependently. However, the amount of MMP-9 and cathepsin K mRNA did not change upon treatment with hemin. Interestingly, cathepsin K levels in cell culture supernatants were not only dose dependently reduced but were completely abolished after addition of 50 µM hemin, suggesting a
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posttranscriptional inhibition (Fig. 3C ). This suggests that HO-1 induction by hemin primarily inhibits osteoclast differentiation.
Hemin down-regulates mRNA levels of c-fms and RANK and reduces RANK, TRAF-6, and c-fos protein expression
To investigate the pathways, by which hemin inhibits osteoclast differentiation, we examined cfms and RANK mRNA expression in the osteoclast assay. RANK-and c-fms mRNA levels were significantly reduced by concentrations of 25 µM hemin and above (Fig. 3D) . Moreover, RANK protein expression was dramatically reduced after treatment with hemin as determined by Western blot analysis (Fig. 3E) . Intracellularly, protein expression of TRAF-6 and c-fos was markedly reduced, supporting the concept that that impaired osteoclast differentiation by hemin maybe due to a down-regulation of responsiveness of pre-osteoclasts to M-CSF and RANKL.
Hemin inhibits TNF-mediated osteoclastogenesis in vitro and inflammatory bone loss in vivo
We next turned to the potential of hemin to impair inflammation-triggered osteoclastogenesis. As previous studies have shown, TNF-α leads to enhanced osteoclastogenesis (25) . Therefore, spleen cells from mice overexpressing human TNF (hTNFtg mice) were cultured with M-CSF and RANKL in the presence or absence of hemin. Treatment with hemin resulted in a dosedependent reduction of osteoclastogenesis in cells from hTNFtg mice compared with wild-type mice. A concentration of 10 µM hemin inhibited osteoclast generation by almost 50%, and concentrations of 50 µM or above completely blocked osteoclast formation (Fig. 4A ). This suggests that hemin blocks TNF-mediated osteoclastogenesis and may interfere with osteoclast formation during inflammation. To evaluate this in more detail, we injected LPS in the calvarial midline of 8-to 12-wk-old mice in vivo. LPS significantly induced osteoclastogenesis after 5 days compared with saline-injected mice (8.6 vs. 1.1 osteoclasts per mm). However, if hemin at a dosage of 20 mg/kg body weight was co-administrated intraperitoneally 1 h before subperiostal LPS injection, LPS-induced osteoclastogenesis could be markedly reduced (3.6 osteoclasts/mm; Fig. 4B ).
HO-1 induction inhibits local osteoclastogenesis in TNF transgenic arthritic mice
To further investigate the anti-osteoclastogenic activity of HO-1 in vivo, we evaluated the potential of CoPP, a potent inducer of HO-1, on blocking bone loss in TNF overexpressing mice. These mice develop a severe destructive polyarthritis with enhanced osteoclastogenesis and massive bone loss along the joints. Treatment with CoPP dramatically diminished osteoclast numbers by >60% (32±6 osteoclasts per paw section, P<0.05 vs. control) as compared with control treatment (62±20 osteoclasts per paw section), when CoPP was administered three times daily. Blockade of osteoclastogenesis by CoPP was associated with diminished bone destruction, when we determined the area of bone erosions. CoPP treatment (0.12±0.03mm 2 , P<0.05 vs. control) significantly reduced the area of local bone erosions as compared with control treatment (0.24±0.03mm
2 ). Hence, HO-1 induction can suppress local bone loss in vivo (Fig. 4C) .
HO-1 is down-regulated in synovial tissue of RA patients at sites of erosions
To investigate if HO-1 could also play a role in the pathomechanisms leading to inflammatory
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joint destruction in human disease, we stained for HO-1 in inflamed joints from RA patients by immunohistochemistry. A strong expression of HO-1 in fibroblasts and macrophages was seen in the synovial lining layer, whereas weaker expression was found in the sublining layers ( Fig. 5A  and B) . In contrast, HO-1 was rarely detectable at sites of subchondral bone destruction. Moreover, positive HO-1 staining was rarely observed in osteoclasts (Fig. 5A and B) . This indicates that HO-1 is down-regulated in human osteoclasts in vivo.
RA patients with bone erosions have lower bilirubin levels compared with nonerosive disease
Since serum bilirubin levels within or slightly above normal values reflect HO-1 activity in humans (26) and reduced HO-1 levels might be associated with increased osteoclast activity, we hypothesized that bilirubin levels could be associated with local bone destruction in patients with RA. For the assessment of total bilirubin levels, we included age and sex matched nonerosive and erosive RA patients, but excluded patients who had elevated liver enzymes or a known hepato-biliar disease. Total bilirubin levels (Fig. 5C ) in nonerosive RA patients were significantly higher (mean 0.65±0.29 mg/dl, median 0.59 mg/dl, minimum 0.27 mg/dl, maximum 1.44 mg/dl) than in the erosive RA patients (mean 0.54±0.18 mg/dl, median 0.51 mg/dl, minimum 0.21 mg/dl, maximum 1.13 mg/dl; P=0.0073). Since erosive RA patients had a significantly longer disease duration than nonerosive patients, we additionally matched the groups for disease duration. This analysis confirmed a significantly higher bilirubin level in nonerosive (mean 0.70±0.30 mg/dl, median 0.62 mg/dl, minimum 0.32 mg/dl, maximum 1.44 mg/dl) as compared with erosive (mean 0.54±0.20 mg/dl, median 0.47 mg/dl, minimum 0.24 mg/dl, maximum 1.00 mg/dl; P=0.0027) RA patients. Thus, lower bilirubin levels indicating lower activity of HO-1 are associated with an increased risk for bone loss in RA.
DISCUSSION
In this study, we investigated the influence of HO-1 on osteoclastogenesis in vitro and in vivo. Our results suggest that 1) induction of HO-1 inhibits osteoclastogenesis in vitro and in vivo; 2) this effect is mediated through down-regulation of surface receptor levels of c-fms and RANK and reduced intracellular expression of TRAF-6 and c-fos leading to impaired osteoclast differentiation; and 3), activity of HO-1 appears to regulate inflammatory bone destruction through its effects on osteoclastogenesis.
HO-1 is the rate-limiting first step of heme degradation, leading to generation of biliverdin, which is then further processed to bilirubin. For this reason, HO-1 is considered to be an important regulatory element of anti-oxidative processes. In fact, HO-1 is induced by oxidants and mediators of inflammation and anti-inflammation, such as endotoxin, IL-10 and 15-deoxyDelta (12, 14)-prostaglandin J2 (15-d-PGJ2) (27, 28) . This induction of HO-1 is accomplished by activation of the mitogen-activated protein cascade (29) . Moreover, the metabolites of HO-1 activity, carbon monoxide and biliverdin, have anti-oxidative properties (30) . Since these in vitro data supported the concept that HO-1 elicits anti-oxidative and anti-inflammatory activity, the role of HO-1 has recently gained scientific interest in in vivo models of inflammatory diseases.
Induction of HO-1 was reported to have beneficial effects on experimental models of glomerulonephritis. Hemin, an inducer of HO-1, inhibits glomerular injury and proteinuria in a model of anti-glomerular basement membrane antibody-mediated glomerulonephritis (10) . Moreover, another study reported that hemin has salutary effects in Mrl/lpr mice, inhibiting formation of autoantibodies against double stranded DNA as well as glomerulonephritis (31) . In addition, HO-1 modifies the severity of LPS-induced inflammatory response. Thus, HO-1 deficient mice are more susceptible to lethal endotoxin induced shock, suggesting that HO-1 mitigates systemic inflammatory response elicited by LPS (32) . Although these studies clearly support an anti-inflammatory effect of HO-1, there is evidence that the interaction of HO-1 with inflammation might be more complex. A study on adjuvant arthritis suggests that inhibition rather than induction of HO-1 positively affects arthritis (33) .
Interestingly, the anti-inflammatory role of HO-1 has been addressed in models that deal with human diseases, such as lupus erythematosus and RA, which are typically associated with bone loss. It is unclear, however, whether HO-1 actually affects bone. Interestingly, excessive iron deposition seems to be a trigger for bone loss, since patients with hemochromatosis have a low bone mass (34) . Our experiments suggest that there is a direct link between HO-1 and bone resorption. Induction of HO-1 potently interfered with osteoclast differentiation. Formation of mature osteoclasts is known to be an essential step for bone resorption (35) . Hemin dose dependently up-regulated HO-1 in osteoclast precursors and inhibited osteoclast differentiation and thus bone resorption. Hemin affected osteoclastogenesis directly, through up-regulation of HO-1 via MAPK-mediated mechanisms in osteoclast precursors, and leads to a blockade of early osteoclast differentiation. Up-regulation of HO-1 via activation of the MAPK cascade is in line with previous observations, reporting that HO-1 induction by prostaglandins and proteasome inhibitors in the RAW macrophage cell line depends on p38MAPK (24) . In contrast, mature osteoclasts were not affected by hemin, indicating that induction of HO-1 primarily interferes with osteoclast differentiation rather than osteoclast function. In agreement with this, no increase of apoptosis, which is a key determinant for the longevity and function of osteoclasts (36) , was observed. The lack of change in cell proliferation supported the notion that inhibition of osteoclast differentiation is the primary target of hemin. This is also backed by the downregulation of key differentiation markers of osteoclasts, such as TRAP, cathepsin K, and the calcitonin receptor. Blocked osteoclastogenesis was due to decreased expression of the M-CSFreceptor c-fms and the RANKL-receptor RANK as well as reduced expression of TRAF-6 and cfos. These signals are essentially required for osteoclast differentiation (37) . By interfering with c-fms and RANK, hemin-induced up-regulation of HO-1 thus appears to render osteoclast precursors inert for further differentiation to the osteoclast lineage.
Hemin affected inflammatory osteoclastogenesis in vitro and in vivo. TNF is a major cofactor for osteoclast differentiation, since it sensitizes osteoclast precursors for RANKL. Thus, TNF augments generation of osteoclasts and, in consequence, favors the negative net effect on bone mass. This is well in line with the low bone mass found in diseases which are TNF-dependent, in particular RA, ankylosing spondylitis and Crohn´s disease (38) (39) (40) . Hemin dose dependently blocked TNF-mediated osteoclastogenesis in vitro. Furthermore, LPS-triggered bone loss, which largely depends on the formation of proinflammatory cytokines, was highly sensitive to hemin treatment in vivo. Thus, a single injection of hemin before endotoxin challenge strongly inhibited osteoclast formation in calvarial bones. In addition, CoPP, another potent inducer of HO-1, significantly inhibited TNF-induced osteoclastogenesis and reduced structural bone damage in human TNFtg mice. These results extend our in vitro observations and indicate that induction of HO-1 negatively regulates osteoclastogenesis and bone loss in vivo. To further determine,
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whether HO-1 may be relevant for osteoclastogenesis and bone destruction in patients, we studied patients with RA. RA is the prototype of disease bridging both inflammation and bone loss. Bone loss in experimental models of arthritis resembling human RA depends on osteoclast formation and inhibition of osteoclastogenesis is a powerful tool to prevent arthritic bone destruction (41) (42) (43) . In human RA, osteoclasts are found at sites of tissue invasion and the current hypothesis suggests that osteoclasts emerge from synovial inflammatory tissue, which provides signals allowing their differentiation from monocytic precursors (44) .
In joint samples from patients with RA, we found numerous osteoclasts attached to bone. Osteoclasts appeared as multinucleated cells that were present at the interface between synovial inflammatory tissue and subchondral bone. Expression of HO-1 was frequently found in cells within the synovial tissue, predominantly by macrophages and fibroblasts in the synovial lining. This observation is well in line with recent data from synovial biopsies from RA patients, showing expression of HO-1 in macrophages and fibroblasts. Interestingly, induction of HO-1 leads to reduced levels of IL-6 and IL-8 in IL-1β stimulated synovial fibroblasts in vitro (unpublished observations). Furthermore, inhibition of HO-1 by siRNA augments TNF-α, IL-6 and IL-8 levels. Expression of HO-1, however, was less frequent in deeper layers of the synovial membrane, such as in the sublining and in subchondral bone erosions. Even more importantly, osteoclasts were usually HO-1 negative, which also indicates that the emergence of osteoclasts depends on the lack of expression of HO-1. We found evidence that bilirubin, a metabolite resulting from heme degradation by HO-1, is associated with a bone erosive state of RA: bilirubin levels were significantly lower in RA patients with erosions as compared with nonerosive RA patients, suggesting that the activity of HO-1 may regulate bone erosion in RA. It thus appears that high activity of HO-1, as manifested by a high serum level of bilirubin, protects from bone erosion in arthritis. These data underline the important regulatory role of HO-1 gained from the Framingham study, which has shown that high bilirubin level, possibly due to high HO-1 activity, protects from cardiovascular disease (45).
In conclusion, we have shown that induction of HO-1 negatively regulates osteoclastogenesis in vitro and in vivo. Furthermore, there is evidence for a regulation of inflammatory bone loss by HO-1 in human disease. The data presented in conjunction with previous evidence of the antiinflammatory potential of HO-1 induction may open new therapeutic avenues for RA. Murine spleen cells were cultivated with 30 ng/ml M-CSF, 50 ng/ml RANKL, and various concentrations of hemin for 4 days. Thereafter, cells were analyzed for cell proliferation by MTT assay (A) and apoptosis by TUNEL staining (B) Dosedependent HO-1 induction by hemin was analyzed in osteoclast precursors after 1 day of culture at mRNA level (C) and protein level (D). E) Immunofluorescence labeling of HO-1 protein induction. F) Western blot analysis of activation of mitogen-activated protein kinases in osteoclast precursors using phospho-specific and control antibodies against p38MAPK, ERK, and JNK. All data are mean ± SE. *Significant difference, P < 0.05. cells from human tumor necrosis factor transgenic (hTNFtg) mice were cultured with 30 ng/ml M-CSF, 50 ng/ml RANKL, and various concentrations of hemin for 5 days. Osteoclasts were stained for TRAP and quantified. Original magnification ×40. B) Wild-type mice were injected sp in the midline calvaria with saline or 25 mg/kg LPS; 20 mg/kg hemin were given ip 1 day before LPS injection. After 5 days, calvarial bones were assessed for osteoclast formation by TRAP staining and quantified by measuring osteclast numbers per mm bone surface. C) 7-wk-old hTNFtg mice were either treated 3 times daily ip with phosphate buffered saline (PBS) or 20 mg/kg CoPP. After 1 wk, mice were killed and hind paws were quantitatively assessed by TRAP staining for osteoclast formation and area of bone erosion. All data are mean ± SE. *Significant difference, P < 0.05. 
